TABLE 2.
PDB IDa | Ligand | Efficacy | Fusion Partnerb | Binding Partner | Resolution (Å) | References |
---|---|---|---|---|---|---|
2RH1 | Carazolol | Inverse agonist | T4 lysozyme (T4L) in ICL3 | None | 2.40 | Cherezov et al., 2007; Rosenbaum et al., 2007 |
2R4R | Carazolol | Inverse agonist | None | Fab5 | 3.40 | Rasmussen et al., 2007 |
2R4S | Carazolol | Inverse agonist | None | Fab5 | 3.40 | Rasmussen et al., 2007 |
3D4S | Timolol | Inverse agonist | T4L in ICL3 | None | 2.80 | Hanson et al., 2008 |
3KJ6 | Carazolol | Inverse agonist | None | Fab5 | 3.40 | Bokoch et al., 2010 |
3NY8 | ICI 118551 | Inverse agonist | T4L in ICL3 | None | 2.84 | Wacker et al., 2010 |
3NY9 | Compound 2ac | Inverse agonist | T4L in ICL3 | None | 2.84 | Wacker et al., 2010 |
3NYA | Alprenolol | Antagonist | T4L in ICL3 | None | 3.16 | Wacker et al., 2010 |
4GBR | Carazolol | Inverse agonist | N-terminal T4L | None | 3.99 | Zou et al., 2012 |
5D5A | Carazolol | Inverse agonist | T4L in ICL3 | None | 2.48 | Huang et al., 2016a |
5D5B | Carazolol | Inverse agonist | T4L in ICL3 | None | 3.80 | Huang et al., 2016a |
5JQH | Carazolol | Inverse agonist | N-terminal T4L | Nanobody Nb60 | 3.20 | Staus et al., 2016 |
5D5B | Carazolol | Inverse agonist | T4L in ICL3 | None | 3.20 | Ma et al., 2017 |
5X7D | Carazolol and intracellular antagonist Cmpd-15PA | Inverse agonist and allosteric antagonist | T4L in ICL3 | None | 2.70 | Liu et al., 2017 |
3PDS | FAUC50 | Covalent agonist | T4L in ICL3 | None | 3.50 | Rosenbaum et al., 2011 |
3P0G | BI-167107 | Full agonist | None | Nanobody Nb80 | 3.50 | Rasmussen et al., 2011a |
3SN6 | BI-167107 | Full agonist | N-terminal T4L | Gs heterotrimer | 3.20 | Rasmussen et al., 2011b |
4LDE | BI-167107 | Full agonist | N-terminal T4L | Nanobody Nb6B9 | 2.79 | Ring et al., 2013 |
4LDL | Hydroxybenzyl isoproterenol | Full agonist | N-terminal T4L | Nanobody Nb6B9 | 3.10 | Ring et al., 2013 |
4LDO | Adrenaline (epinephrine) | Full agonist | N-terminal T4L | Nanobody Nb6B9 | 3.20 | Ring et al., 2013 |
4QKX | Compound 2bc | Covalent agonist | N-terminal T4L | Nanobody Nb6B9 | 3.30 | Weichert et al., 2014 |
6MXT | Salmeterol | Partial agonist | N-terminal T4L | Nanobody Nb71 | 2.96 | Masureel et al., 2018 |
PDB, https://www.rcsb.org/.
Inserting a small protein into GPCRs either at the ICL3 or at the N-terminal ends has been widely used to facilitate crystallization.
Compound 2a and compound 2b are unrelated. They were both named “compound 2” in the literature. Here we use 2a and 2b to avoid confusion.
ICL3, intracellular loop 3.